Core Viewpoint - The stock of Jibeier has experienced fluctuations, with a recent decline of 2.00% and a total market value of 5.863 billion yuan, reflecting mixed investor sentiment and trading activity [1]. Group 1: Stock Performance - As of January 15, Jibeier's stock price is 29.40 yuan per share, with a trading volume of 39.944 million yuan and a turnover rate of 0.67% [1]. - Year-to-date, the stock has decreased by 1.51%, with a 3.29% drop over the last five trading days, a 4.11% increase over the last 20 days, and a 9.48% decline over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million yuan, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million yuan, up by 12.80% [2]. Group 3: Shareholder Information - As of January 9, 2025, Jibeier has 7,406 shareholders, an increase of 3.35% from the previous period, with an average of 26,928 circulating shares per shareholder, a decrease of 3.24% [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million yuan in dividends, with 252 million yuan distributed over the last three years [3]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed A (011201) and GF Healthcare Stock A (004851), holding 1.2392 million shares and 959,000 shares respectively [3].

Group 1 - The core point of the article is that as of January 9, 2026, the total number of shareholders for the company is 7,406 [1]

Core Viewpoint - Shanghai Gaochong Technology Development Co., Ltd. has been established with a registered capital of 10 million RMB, fully owned by Jiangsu Jibeier Pharmaceutical Co., Ltd. [1] Group 1: Company Information - The legal representative of Shanghai Gaochong Technology Development Co., Ltd. is Liu Binghai [1] - The company is classified as a limited liability company with a business scope that includes technology services, development, consulting, and sales of specialized chemical products [1] - The registered address of the company is located at 668 Shangda Road, Building 1, 5th Floor, Area B, Baoshan District, Shanghai [1] Group 2: Shareholding Structure - Jiangsu Jibeier Pharmaceutical Co., Ltd. holds 100% of the shares in Shanghai Gaochong Technology Development Co., Ltd. [1] Group 3: Business Operations - The business operations include medical research and experimental development, marketing planning, conference and exhibition services, ticketing agency services, business secretary services, and technology intermediary services [1] - The company is authorized to conduct business activities independently based on its business license, except for projects that require approval by law [1] Group 4: Registration and Duration - The business registration is valid until January 8, 2026, with no fixed term thereafter [1] - The registration authority is the Baoshan District Market Supervision Administration [1]

Group 1 - The company is currently preparing for the production approval application of the antidepressant drug JJH201501 [2] - The company stated that it will accelerate the application process in accordance with relevant requirements [2] - Investors are encouraged to pay attention to the company's future disclosures regarding the progress of the application [2]

Core Viewpoint - The company, Jibeier, announced that it will disclose the number of shareholders in its 2025 annual report to ensure fairness in information disclosure [1] Group 1 - The company responded to investor inquiries regarding the number of shareholders at the end of the reporting period [1] - The information about the number of shareholders is considered a periodic report disclosure requirement [1] - The company aims to maintain transparency and fairness in its information disclosure practices [1]

Group 1 - The core point of the news is that Jibeier Pharmaceutical Co., Ltd. experienced a stock decline of 1.01%, with a current share price of 29.27 yuan and a total market capitalization of 5.837 billion yuan [1] - Jibeier's main business involves drug research, production, and sales, with the revenue composition being: Likujun tablets 72.72%, Niquinlor tablets 14.20%, Yupingfeng capsules 4.88%, others 4.53%, and Acetylsalicylic acid enteric-coated tablets 3.67% [1] Group 2 - Among Jibeier's top ten circulating shareholders, one fund from GF Fund Management, the GF Healthcare Stock A (004851), entered the top ten in the third quarter, holding 959,000 shares, which is 0.48% of the circulating shares [2] - The GF Healthcare Stock A fund has a total size of 5.185 billion yuan, with a year-to-date return of 10.16%, ranking 3520 out of 4195 in its category [2] - The fund manager, Wu Xingwu, has a tenure of 10 years and 325 days, with the fund's total asset size at 10.641 billion yuan and a best return of 85.08% during his tenure [3]

Core Viewpoint - The company has completed the initial public offering (IPO) fundraising project related to the construction of a new research and development center and plans to permanently supplement its working capital with the surplus funds of 28.4987 million yuan [1][3]. Fundraising Basic Situation - The company raised a total of 1,107.161626 billion yuan from the IPO, with a net amount of 1,020.88846119 billion yuan after deducting issuance costs of 86.27316481 million yuan [1][2]. Surplus Fund Situation - The surplus amount of 28.4987 million yuan includes bank interest and cash management income, which will be used to support the company's daily operations and business development needs [3][4]. Project Implementation Progress Adjustment - The company has adjusted the implementation timeline for certain fundraising projects, including the production base construction and the development of new drugs, extending deadlines to ensure compliance with quality management standards [6][7]. Measures for Project Implementation - The company will strictly adhere to relevant regulations and optimize resource allocation to ensure the effective implementation of the fundraising projects [8][9]. Review Procedures and Sponsor Opinions - The board of directors has approved the project adjustments and the use of surplus funds, confirming that the decisions comply with regulatory requirements and do not harm shareholder interests [10][11].

国金证券股份有限公司 关于江苏吉贝尔药业股份有限公司 首发募投项目调整实施进度的核查意见 国金证券股份有限公司（以下简称"国金证券"、"保荐机构"）作为江苏 吉贝尔药业股份有限公司（以下简称"吉贝尔"、"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对吉贝尔 部分首发募投项目结项并将节余募集资金永久补流、部分首发募投项目调整实施 进度事项进行了审慎核查，并发表核查意见如下： | 发行名称 | 2020 | 年首次公开发行股份 | | | --- | --- | --- | --- | | 募集资金总额 | | 110,716.16 | 万元 | | 募集资金净额 | | 102,088.85 | 万元 | | 募集资金到账时间 | 2020 | 年 月 5 | 日 12 | 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）2020 年 4 月 7 日 作出的《关于同意江苏吉贝尔药业股份有限公司首次公 ...

江苏吉贝尔药业股份有限公司 关于部分首发募投项目结项并将节余募集资金永久 补流、部分首发募投项目调整实施进度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688566 证券简称：吉贝尔 公告编号：2025-051 本次结项的首次公开发行股票募集资金投资项目（简称"首发募投项 目"或"募投项目"）名称：研发中心（新址）建设项目 本次节余金额为 2,849.87 万元，下一步使用安排是永久补充流动资金 结合目前首发募投项目"利可君片、尼群洛尔片、玉屏风胶囊、盐酸 洛美沙星滴眼液、益肝灵胶囊等生产基地（新址）建设项目"、"国家一类抗 抑郁新药（JJH201501）、国家一类抗肿瘤新药（JJH201601）研发与试验项 目"的实施情况，拟对项目实施进度进行调整 一、募集资金基本情况 | 发行名称 | 2020 | 年首次公开发行股份 | | | | | --- | --- | --- | --- | --- | --- | | 募集资金总额 | | 万元 110,716.16 | | | | | ...

Core Viewpoint - The company announced the conclusion of certain fundraising projects and the permanent allocation of surplus funds to working capital, indicating a strategic adjustment in project implementation timelines [1] Group 1: Project Conclusion - The company held its 19th meeting of the fourth board of directors on December 29, 2025, where it approved the conclusion of the "Research and Development Center (New Site) Construction Project," which has reached the predetermined usable state [1] - The surplus funds from this project amount to 28.4987 million yuan, including bank interest and cash management income, which will be permanently allocated to working capital [1] Group 2: Fund Management - After the transfer of all raised funds, the company will cancel the corresponding special account for the raised funds, indicating a streamlined approach to fund management [1]